Dietary supplementation with the Omega-3 fatty acid docosahexaenoic acid in traumatic brain injury

Neurosurgery

Volumn 68, Issue 2, 2011, Pages 474-481

  Mills, James D ^a   Hadley, Kevin ^b   Bailes, Julian E ^a  

^a WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Martek Biosciences Corporation   (United States)

Author keywords

Amyloid precursor protein (APP); Caspase 3 CD68; Docosahexaenoic acid (DHA); Omega 3 fatty acids; Traumatic brain injury

Indexed keywords

AMYLOID PRECURSOR PROTEIN; CASPASE 3; CD68 ANTIGEN; DOCOSAHEXAENOIC ACID; FATTY ACID; PHOSPHOLIPID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BEHAVIOR; BRAIN STEM; CELL DAMAGE; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG MEGADOSE; FLUORESCENCE; IMMUNOHISTOCHEMISTRY; LABELING INDEX; MALE; MAZE TEST; MEMORY; NERVE FIBER; NONHUMAN; PHOSPHOLIPID BLOOD LEVEL; PRIORITY JOURNAL; RAT; STEREOLOGY; TRAUMATIC BRAIN INJURY; TREATMENT OUTCOME; WHITE MATTER;

ANIMALS; BRAIN; BRAIN INJURIES; DIETARY SUPPLEMENTS; DOCOSAHEXAENOIC ACIDS; IMMUNOHISTOCHEMISTRY; MALE; MAZE LEARNING; NEUROPROTECTIVE AGENTS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 79951681717     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1227/NEU.0b013e3181ff692b     Document Type: Article

References (47)

1. Leys D, Balucani C, Cordonnier C. Antiplatelet drugs for ischemic stroke prevention. Cerebrovasc Dis. 2009;27(Suppl 1):120-125.
2. Diener HC. Stroke prevention: Anti-platelet and anti-thrombolytic therapy. Neurol Clin. 2000;18(2):343-355.
3. Wolff T, Witkop CT, Miller T, Syed SB. Folic acid supplementation for the prevention of neural tube defects: An update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2009;150(9):932-939.
4. Cucchiara B, Kasner SE. Use of statins in CNS disorders. J Neurol Sci. 2001;187(1-2):81-89. (Pubitemid 32611661)
5. Rajanikant GK, Zemke D, Kassab M, Majid A. The therapeutic potential of statins in neurological disorders. Curr Med Chem. 2007;14(1):103-112. (Pubitemid 46050307)
6. Vaughan CJ, Delanty N. Neuroprotective properties of statins in cerebral ischemia and stroke. Stroke. 2000;30(9):1969-1973.
7. Doraiswamy PM. Non-cholinergic strategies for treating and preventing Alzheimer's disease. CNS Drugs. 2002;16(12):811-824. (Pubitemid 35440615)
8. Freiberg JJ, Tybjaerg-Hansen A, Jensen JS, Nordestgaard BG. Nonfasting triglycerides and risk of ischemic stroke in the general population. JAMA. 2008;300(18):2142-2152.
9. Moreira PI, Zhu X, Nunomura A, Smith MA, Perry G. Therapeutic options in Alzheimer's disease. Expert Rev Neurother. 2006;6(6):897-910. (Pubitemid 43961890)
10. ShahRS, LeeHG, Xiongwei Z, PerryG, SmithMA,CastellaniRJ. Current approaches in the treatment of Alzheimer's disease. Biomed Pharmacother. 2007;62(4):199-207.
11. Wilcock DM, Colton CA. Anti-amyloid-beta immunotherapy in Alzheimer's disease: Relevance of transgenic mouse studies to clinical trials. J Alzheimers Dis. 2008;15(4):555-569.
12. Jain KK. Neuroprotection in traumatic brain injury. Drug Discov Today. 2008;13(23-24):1082-1089.
13. Mills JD, Sedney CL, Shih SR, Bailes JE. Omega 3 dietary supplementation reduces traumatic axonal injury in a rodent head injury model. J Neurosurg. 2010 July 16 (Epub ahead of print).
14. Bailes JE, Mills JD. Docosahexaenoic acid reduces traumatic axonal injury in a rodent head injury model. J Neurotrauma. 2010;27(9):1617-1624.
15. Marmarou A, Foda MA, van den BW, Campbell J, Kita H, Demetriadou K. A new model of diffuse brain injury in rats. Part 1: Pathophysiology and biomechanics. J Neurosurg. 1994;80(2):291-300. (Pubitemid 24036501)
16. Stone JR, Walker SA, Povlishock JT. The visualization of a new class of traumatically injured axons through the use of a modified method of microwave antigen retrieval. Acta Neuropathol (Berl). 1999;97(4):4,335-345.
17. Mills JD, Stone JR, Melon DE, Okonkwo DO, Periasamy A, Helm GA. Illuminating protein interactions in tissue using confocal and two-photon excitation fluorescent resonance energy transfer microscopy. J Biomed Optics. 2003;8(3):347-356.
18. Huang WL, King VR, Curran OE, et al. A combination of intravenous and dietary docosahexaenoic acid significantly improves outcome after spinal cord injury. Brain. 2007;130(Pt 11):3004-3019. (Pubitemid 350033967)
19. Wang HG, Pathan N, Ethell IM, et al. Ca2+induced apoptosis through calcineurin dephosphorylation of BAD. Science. 1999;284(5412):339-343. (Pubitemid 129523456)
20. Wu A, Ying Z, Gomez-Pinilla F. Omega-3 fatty acids supplementation restores mechanisms that maintain brain homeostasis in traumatic brain injury. J Neurotrauma. 2007;24(10):1587-1594.
21. Bazan NG. Neuroprotectin D1 (NPD1): A DHA-derived mediator that protects brain and retina against cell injury-induced oxidative stress. Brain Pathol. 2005;15(2):159-166. (Pubitemid 40546172)
22. Hogyes E, Nyakas C, Kiliaan A, Farkas T, Penke B, Luiten PG. Neuroprotective effect of developmental docosahexaenoic acid supplement against excitotoxic brain damage in infant rats. Neuroscience. 2003;119(4):999-1012. (Pubitemid 36776450)
23. Roberts L, Bailes J, Dedhia H, et al. Surviving a mine explosion. J Am Coll Surg. 2008;207(2):276-283.
24. Heller AR, Rossler S, Litz RJ, et al. Omega-3 fatty acids improve the diagnosisrelated clinical outcome. Crit Care Med. 2006;34(4):972-979.
25. Martinez M. Tissue levels of polyunsaturated fatty acids during early human development. J Pediatr. 1992;120(4 Pt 2):S129-S138.
26. Cao DH, Xu JF, Xue RH, Zheng WF, Liu ZL. Protective effect of chronic ethyl docosahexaenoate administration on brain injury in ischemic gerbils. Pharmacol Biochem Behav. 2004;79(4):651-659.
27. Salem N Jr, Litman B, Kim HY, Gawrisch K. Mechanisms of action of docosahexaenoic acid in the nervous system. Lipids. 2001;36:945-959. (Pubitemid 33065196)
28. Needleman P, Raz A, Minkes MS, Ferrendelli JA, Sprecher H. Triene prostaglandins: Prostacyclin and thromboxane biosynthesis and unique biological properties. Proc Natl Acad Sci U S A. 1979;76(2):944-948. (Pubitemid 9130979)
29. Pan H-C, Kao T-K, Ou Y-C, et al. Protective effect of docosahexaenoic acid against brain injury in ischemic rats. J Nutr Biochem. 2009;20(9):715-725.
30. Choi JS, Kim HY, Cha JH, Lee MY. Ischemic preconditioning-induced activation of ERK ü in the rat hippocampus. Neurosci Lett. 2006;409(3):187-191.
31. Belayev L, Khoutorova L, Atkins KD, Bazan NG. Robust docosahexaenoic acidmediated neuroprotection in a rat model of transient, focal cerebral ischemia. Stroke. 2009;40(9):3121-3126.
32. Berman DR, Mozurkewich E, Lui Y, Barks J. Docosahexaenoic acid pretreatment confers neuroprotection in a rat model of perinatal cerebral hypoxia-ischemia. Am J Obstet Gynecol. 2009;200(3):305.e1-e6.
33. Babcock AA, Wirenfeldt M, Holm T, et al. Toll-like receptor 2 signaling in response to brain injury: An innate bridge to neuroinflammation. J Neurosci. 2006;26(49):12826-12837. (Pubitemid 44904578)
34. Calder PC. Long-chain n-3 fatty acids and inflammation: Potential application in surgical and trauma patients. Braz J Med Biol Res. 2003;36(4):433-446. (Pubitemid 36592146)
35. Lonergan PE, Martin DS, Horrobin DF, Lynch MA. Neuroprotective actions of eicosapentaenoic acid on lipopolysaccharide-induced dysfunction in rat hippocampus. J Neurochem. 2004;91(1):20-29. (Pubitemid 39314933)
36. Calderon F, Kim HY. Docosahexaenoic acid promotes neurite growth in hippocampal neurons. J Neurochem. 2004;90(4):979-988. (Pubitemid 39099980)
37. Desire L, Courtois Y, Jeanny JC. Endogenous and exogenous fibroblast growth factor 2 support survival of chick retinal neurons by control of neuronal bcl-x(L) and bcl-2 expression through a fibroblast growth factor receptor 1-And ERKdependent pathway. J Neurochem. 2000;75(1):151-163. (Pubitemid 30418180)
38. He C, Qu X, Cui L, Want J, Kang JX. Improved spatial learning performance of fat-1 mice is associated with enhanced neurogenesis and neuritogenesis by docosahexaenoic acid. Proc Natl Acad Sci U S A. 2009;106(27):11370-11375.
39. Blondeau N, Widmann C, Lazdunski M, Heurteaux C. Polyunsaturated fatty acids induce ischemic and epileptic tolerance. Neuroscience. 2002;109(2):231-241. (Pubitemid 34098964)
40. Wang X, Zhao X, Mao ZY, Wang XM, Liu ZL. Neuroprotective effect of docosahexaenoic acid on glutamate-induced cytotoxicity in rat hippocampal cultures. NeuroReport. 2003;14(18):2457-2461.
41. Homayoun P, Rodriguez de Turco EB, Parkins NE. Delayed phospholipid degradation in rat brain after traumatic brain injury. J Neurochem. 1997;69(1): 199-205. (Pubitemid 27274173)
42. Lauritzen I, Blondeau N, Heurteaux C, Widmann C, Romey G, Lazdunski M. Polyunsaturated fatty acids are potent neuroprotectors. Embo J. 2000;19(8):1784-1793. (Pubitemid 30204390)
43. Li W, Sperry JB, Crowe A, Trojanowski JQ, Smith AB III, Lee VM. Inhibition of tau fibrillation by oleocanthal via reaction with the amino group of tau. J Neurochem. 2009;110(4):1339-1351.
44. Jump DB. Dietary polyunsaturated fatty acids and regulation of gene transcription. Curr Opin Lipidol. 2002;13(2):155-164. (Pubitemid 34280767)
45. Mukherjee PK, Marcheselli VL, Serhan CN, Bazan NG. Neuroprotectin D1: A docosahexaenoic acid-derived docosatriene protects human retinal pigment epithelial cells from oxidative stress. Proc Natl Acad Sci U S A. 2004;101(22): 8491-8496. (Pubitemid 38736602)
46. Marklund N, Salci K, Lewen A, Hillered L. Glycerol as a marker for post-traumatic membrane phospholipid degradation in rat brain. Neuroreport. 1997;8(6):1457-1461. (Pubitemid 27242554)
47. Buki A, Povlishock JT. All roads lead to disconnection?-traumatic axonal injury revisited. Acta Neurochir. 2006;148(2):181-194.